News
A Houston-based compounding pharmacy that was recently roped into Eli Lilly’s fight against knockoff GLP-1s has landed in the ...
In December 2024, the FDA affirmed that the shortage of tirzepatide, marketed as Zepbound for weight loss, had ended, ...
Eli Lilly escalates its crackdown on unauthorized tirzepatide copies, filing lawsuits against four compounders accused of ...
Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...
1h
Zacks Investment Research on MSNIs Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings?Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate ...
Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ...
4d
Pharmaceutical Technology on MSNEli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketingMochi Health Corp, Fella Health and Delilah, Willow Health Services, and Henry Meds are the named companies in Eli Lilly’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results